IS2514B - Bót á kerfalosti og andnauð, sem veirur valda, með stöðvun lífvessaeiturefnis-beta-ferlisins - Google Patents

Bót á kerfalosti og andnauð, sem veirur valda, með stöðvun lífvessaeiturefnis-beta-ferlisins

Info

Publication number
IS2514B
IS2514B IS5882A IS5882A IS2514B IS 2514 B IS2514 B IS 2514B IS 5882 A IS5882 A IS 5882A IS 5882 A IS5882 A IS 5882A IS 2514 B IS2514 B IS 2514B
Authority
IS
Iceland
Prior art keywords
beta
respiratory distress
remediation
bioavailability
viruses
Prior art date
Application number
IS5882A
Other languages
English (en)
Other versions
IS5882A (is
Inventor
Jeff Browning
Maryann Puglielli
Rafi Ahmed
Original Assignee
Biogen Idec Inc
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Univ Emory filed Critical Biogen Idec Inc
Publication of IS5882A publication Critical patent/IS5882A/is
Publication of IS2514B publication Critical patent/IS2514B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IS5882A 1998-10-09 2001-03-09 Bót á kerfalosti og andnauð, sem veirur valda, með stöðvun lífvessaeiturefnis-beta-ferlisins IS2514B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10366298P 1998-10-09 1998-10-09
PCT/US1999/023477 WO2000021558A1 (en) 1998-10-09 1999-10-08 Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway

Publications (2)

Publication Number Publication Date
IS5882A IS5882A (is) 2001-03-09
IS2514B true IS2514B (is) 2009-06-15

Family

ID=22296372

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5882A IS2514B (is) 1998-10-09 2001-03-09 Bót á kerfalosti og andnauð, sem veirur valda, með stöðvun lífvessaeiturefnis-beta-ferlisins

Country Status (27)

Country Link
US (3) US20020001585A1 (is)
EP (1) EP1119370B1 (is)
JP (2) JP4713738B2 (is)
KR (1) KR100888832B1 (is)
CN (1) CN1200733C (is)
AT (1) ATE329618T1 (is)
AU (1) AU777492C (is)
BR (1) BR9915025A (is)
CA (1) CA2344049C (is)
CY (1) CY1105059T1 (is)
CZ (1) CZ20011272A3 (is)
DE (1) DE69931944T2 (is)
DK (1) DK1119370T3 (is)
EA (1) EA006703B1 (is)
EE (1) EE04661B1 (is)
ES (1) ES2267294T3 (is)
HU (1) HUP0103773A3 (is)
IL (2) IL142284A0 (is)
IS (1) IS2514B (is)
NO (1) NO326905B1 (is)
NZ (1) NZ510560A (is)
PL (1) PL195264B1 (is)
PT (1) PT1119370E (is)
SG (1) SG121778A1 (is)
SK (1) SK4662001A3 (is)
TR (1) TR200100974T2 (is)
WO (1) WO2000021558A1 (is)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
WO2000021558A1 (en) * 1998-10-09 2000-04-20 Biogen, Inc. Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
WO2001079496A2 (en) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
AU5338701A (en) * 2000-04-12 2001-10-30 Jolla Inst Allergy Immunolog Ligand for herpes simplex virus entry mediator and methods of use
US20050163782A1 (en) * 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
SG151294A1 (en) * 2004-03-23 2009-04-30 Biogen Idec Inc Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
JP2010506955A (ja) 2006-10-20 2010-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 可溶性リンホトキシンβレセプターによる脱髄障害の処置
EP3750554A3 (en) * 2007-09-18 2021-07-28 La Jolla Institute for Allergy and Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
CN106591446A (zh) * 2016-12-07 2017-04-26 中国人民解放军军事医学科学院微生物流行病研究所 细胞通路调控分子在作为药物靶点及诊断ebov感染中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US7030080B2 (en) * 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
ATE201879T1 (de) * 1990-06-27 2001-06-15 Biogen Inc Oberflächenkomplexbildung von lymphotoxin
US5795964A (en) * 1990-06-27 1998-08-18 Biogen, Inc. Lymphotoxin-beta and lymphotoxin-beta complexes
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0672143B1 (en) 1992-12-04 2008-06-04 Biogen Idec MA Inc. Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
DK0809510T3 (da) 1995-01-26 2004-10-04 Biogen Inc Lymphotoxin-alfa/beta-komplekser og antilymphotoxin-beta-receptorantistoffer som antitumormidler
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
NZ335353A (en) * 1996-10-25 2000-09-29 Biogen Inc Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases including AIDS or HIV
US7255854B1 (en) * 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
WO2000021558A1 (en) * 1998-10-09 2000-04-20 Biogen, Inc. Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies

Also Published As

Publication number Publication date
NZ510560A (en) 2003-09-26
HUP0103773A3 (en) 2003-10-28
EE200100211A (et) 2002-08-15
DK1119370T3 (da) 2006-10-02
SK4662001A3 (en) 2001-11-06
NO20011757D0 (no) 2001-04-06
WO2000021558A1 (en) 2000-04-20
IS5882A (is) 2001-03-09
CY1105059T1 (el) 2010-03-03
TR200100974T2 (tr) 2001-11-21
US20040198635A1 (en) 2004-10-07
NO20011757L (no) 2001-06-08
US20020001585A1 (en) 2002-01-03
AU777492B2 (en) 2004-10-21
IL142284A0 (en) 2002-03-10
US20090087403A1 (en) 2009-04-02
EA006703B1 (ru) 2006-02-24
CA2344049A1 (en) 2000-04-20
CN1200733C (zh) 2005-05-11
AU777492C (en) 2005-05-26
CZ20011272A3 (cs) 2001-09-12
CN1323223A (zh) 2001-11-21
IL142284A (en) 2009-11-18
EE04661B1 (et) 2006-08-15
EP1119370A1 (en) 2001-08-01
ATE329618T1 (de) 2006-07-15
HUP0103773A2 (hu) 2002-01-28
KR20010080073A (ko) 2001-08-22
ES2267294T3 (es) 2007-03-01
NO326905B1 (no) 2009-03-16
DE69931944D1 (de) 2006-07-27
PL347177A1 (en) 2002-03-25
JP4713738B2 (ja) 2011-06-29
CA2344049C (en) 2009-12-15
JP2002527403A (ja) 2002-08-27
PT1119370E (pt) 2006-09-29
EP1119370B1 (en) 2006-06-14
JP2010155852A (ja) 2010-07-15
WO2000021558A9 (en) 2001-05-25
EA200100430A1 (ru) 2001-10-22
BR9915025A (pt) 2001-08-14
SG121778A1 (en) 2006-05-26
PL195264B1 (pl) 2007-08-31
AU6296499A (en) 2000-05-01
US7452530B2 (en) 2008-11-18
DE69931944T2 (de) 2007-02-08
KR100888832B1 (ko) 2009-03-17

Similar Documents

Publication Publication Date Title
IS2514B (is) Bót á kerfalosti og andnauð, sem veirur valda, með stöðvun lífvessaeiturefnis-beta-ferlisins
EP0111993A3 (en) Improvements in or relating to benzimidazoles
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
MXPA04001889A (es) Inhibidores de la alquin-aril fosfodiesterasa-4.
BR0012243A (pt) Triflúor butenos nematocidas
YU82702A (sh) Ortosupstituisani amidi antranilne kiseline i njihova primena kao sredstva za lečenje
SE0004710D0 (sv) System och förfarande
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
DE60023333D1 (de) Schaukel für behinderte
NO970573D0 (no) Ylidenforbindelser og deres fremstilling
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
PL338147A1 (en) Derivatives of polyhydroxylbutylpyrazine, method of obtaining and drugs containing them
DK1478360T3 (da) Midler, der interagerer med en serotonin-transportör, til behandling af cancer
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.
DK1062237T3 (da) Metalholdige ribonukleotid-polypeptider
ES2193285T3 (es) Inhibidor de oxido nitrico (no)-sintasa para prevenir la diabetes de tipo ii.
ATE179987T1 (de) Vitamin b 12-haltige sanddornkonzentrate oder - extrakte
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії
UA36385A (uk) Спосіб лікування генералізованого пародонтиту
NO20000554L (no) Produkt inneholdende minst en dobbelt trådet RNA i kombinasjon med minst et 6-benzyluracilderivat
RO115404B1 (ro) Dispozitiv de termoterapie
UA35854A (uk) Спосіб лікування приховано протікаючого силікотуберкульозу
UA38418A (uk) Засіб для стимуляції регенеративних процесів в інсулінпродукуючому апараті підшлункової залози